Cargando…
Durable remission after treatment with very low doses of imatinib for FIP1L1-PDGFRα-positive chronic eosinophilic leukaemia
Autores principales: | Helbig, Grzegorz, Moskwa, Andrzej, Hus, Marek, Piszcz, Jarosław, Swiderska, Alina, Urbanowicz, Alina, Całbecka, Małgorzata, Seferyńska, Ilona, Raźny, Małgorzata, Rodzaj, Marek, Żuk, Ewa, Kyrcz-Krzemień, Sławomira |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3064899/ https://www.ncbi.nlm.nih.gov/pubmed/21327932 http://dx.doi.org/10.1007/s00280-011-1582-3 |
Ejemplares similares
-
New drugs in multiple myeloma – role of carfilzomib and pomalidomide
por: Jurczyszyn, Artur, et al.
Publicado: (2014) -
Characteristics and clinical outcome of patients with hypereosinophilia of undetermined significance
por: Helbig, Grzegorz, et al.
Publicado: (2013) -
The Efficacy of Cladribine (2-CdA) in Advanced Systemic Mastocytosis
por: Helbig, Grzegorz, et al.
Publicado: (2020) -
Occurrence of Secondary Malignancies in Chronic Myeloid Leukemia During Therapy with Imatinib Mesylate-Single Institution Experience
por: Helbig, Grzegorz, et al.
Publicado: (2015) -
Clinical relevance of mutant NPM1 and CEBPA in patients with acute myeloid leukaemia – preliminary report
por: Helbig, Grzegorz, et al.
Publicado: (2014)